174 related articles for article (PubMed ID: 31945355)
21. Infliximab-induced lupus in Crohn's disease: a case report.
Sarzi-Puttini P; Ardizzone S; Manzionna G; Atzeni F; Colombo E; Antivalle M; Carrabba M; Bianchi-Porro G
Dig Liver Dis; 2003 Nov; 35(11):814-7. PubMed ID: 14674674
[TBL] [Abstract][Full Text] [Related]
22. Tumour necrosis factor-alpha inhibitor induced recurrent symptomatic hypoglycaemia.
Mah JY; Teng J; Gilfillan C
Intern Med J; 2019 Nov; 49(11):1460-1461. PubMed ID: 31713334
[No Abstract] [Full Text] [Related]
23. Severe Eosinophilic Gastroenteritis in a Crohn's Disease Patient Treated With Infliximab and Adalimumab.
Muir A; Surrey L; Kriegermeier A; Shaikhkalil A; Piccoli DA
Am J Gastroenterol; 2016 Mar; 111(3):437-8. PubMed ID: 27018120
[No Abstract] [Full Text] [Related]
24. Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review.
Da W; Zhu J; Wang L; Lu Y
Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):885-91. PubMed ID: 23817447
[TBL] [Abstract][Full Text] [Related]
25. Prospective Evaluation of the Achievement of Mucosal Healing with Anti-TNF-α Therapy in a Paediatric Crohn's Disease Cohort.
Nuti F; Civitelli F; Bloise S; Oliva S; Aloi M; Latorre G; Viola F; Cucchiara S
J Crohns Colitis; 2016 Jan; 10(1):5-12. PubMed ID: 26188350
[TBL] [Abstract][Full Text] [Related]
26. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
Narula N; Kainz S; Petritsch W; Haas T; Feichtenschlager T; Novacek G; Eser A; Vogelsang H; Reinisch W; Papay P
Aliment Pharmacol Ther; 2016 Jul; 44(2):170-80. PubMed ID: 27226407
[TBL] [Abstract][Full Text] [Related]
27. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.
Ramos-Casals M; Brito-Zerón P; Muñoz S; Soria N; Galiana D; Bertolaccini L; Cuadrado MJ; Khamashta MA
Medicine (Baltimore); 2007 Jul; 86(4):242-251. PubMed ID: 17632266
[TBL] [Abstract][Full Text] [Related]
28. Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease.
Taxonera C; Robledo P; Rodríguez A
Rev Esp Enferm Dig; 2017 Oct; 109(10):690-693. PubMed ID: 28747060
[TBL] [Abstract][Full Text] [Related]
29. Case of psoriasiform and pustular eruptions in addition to alopecia as a paradoxical reaction induced by infliximab.
Shimokata M; Namiki T; Tokoro S; Ugajin T; Miura K; Yokozeki H
J Dermatol; 2018 Dec; 45(12):e331-e333. PubMed ID: 29855072
[No Abstract] [Full Text] [Related]
30. Severe Attack of Henoch-Schönlein Purpura With Neurological Involvement During Adalimumab Treatment for Crohn's Disease.
Condamina M; Diaz E; Jamart C; Loget J; Durlach A; Salmon JH; Cadiot G; Viguier M
J Crohns Colitis; 2020 May; 14(4):538-542. PubMed ID: 31589303
[TBL] [Abstract][Full Text] [Related]
31. Anti-TNF dose escalation and drug sustainability in Crohn's disease: Data from the nationwide administrative database in Hungary.
Kósa F; Kunovszki P; Borsi A; Iliás Á; Palatka K; Szamosi T; Vincze Á; Molnár T; Lakatos PL
Dig Liver Dis; 2020 Mar; 52(3):274-280. PubMed ID: 31669077
[TBL] [Abstract][Full Text] [Related]
32. [IgA vasculitis associated with anti-TNF-α inhibitors in a patient with Crohn's disease].
Nishikawa J; Hosokawa A; Akashi M; Mihara H; Nanjo S; Yoshita H; Ando T; Kajiura S; Fujinami H; Sugiyama T
Nihon Shokakibyo Gakkai Zasshi; 2015 Oct; 112(10):1852-7. PubMed ID: 26440688
[TBL] [Abstract][Full Text] [Related]
33. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.
Stoppino LP; Della Valle N; Rizzi S; Cleopazzo E; Centola A; Iamele D; Bristogiannis C; Stoppino G; Vinci R; Macarini L
BMC Med Imaging; 2016 May; 16(1):37. PubMed ID: 27149857
[TBL] [Abstract][Full Text] [Related]
34. Outcome after a dose "de-intensification" strategy with anti-TNF drugs in patients with Crohn's disease.
Chaparro M; Barreiro-de Acosta M; García-Planella E; Domènech E; Bermejo F; Calvet X; Martín Arranz MD; Monfort D; Gisbert JP
Gastroenterol Hepatol; 2016 Apr; 39(4):255-60. PubMed ID: 26620278
[TBL] [Abstract][Full Text] [Related]
35. Positive antiphospholipid antibodies and pulmonary embolism in a patient with adalimumab-induced lupus.
Uehara M; Matsushita S; Aochi S; Yamamoto M
Mod Rheumatol Case Rep; 2023 Jan; 7(1):68-73. PubMed ID: 36208152
[TBL] [Abstract][Full Text] [Related]
36. Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent.
Subramanian S; Yajnik V; Sands BE; Cullen G; Korzenik JR
Inflamm Bowel Dis; 2011 Jan; 17(1):99-104. PubMed ID: 20629183
[TBL] [Abstract][Full Text] [Related]
37. Fourteen-Year Anti-TNF Therapy in Crohn's Disease Patients: Clinical Characteristics and Predictive Factors.
Osamura A; Suzuki Y
Dig Dis Sci; 2018 Jan; 63(1):204-208. PubMed ID: 29209921
[TBL] [Abstract][Full Text] [Related]
38. Henoch-Schönlein purpura during anti-TNFα therapy: a fortuitous event or an indication to stop therapy?
Pinheiro RR; Lencastre A
Eur J Dermatol; 2017 Jun; 27(3):304-305. PubMed ID: 28468732
[No Abstract] [Full Text] [Related]
39. SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB.
Bau M; Zacharias P; Ribeiro DA; Boaron L; Steckert Filho A; Kotze PG
Arq Gastroenterol; 2017 Dec; 54(4):328-332. PubMed ID: 28954043
[TBL] [Abstract][Full Text] [Related]
40. A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab.
Yokoyama K; Yamazaki K; Katafuchi M; Ferchichi S
Adv Ther; 2016 Nov; 33(11):1947-1963. PubMed ID: 27664107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
